SBH Sciences is an innovative preclinical contract research organization (CRO), focused on anti-cancer and anti-inflammation drug development. In its 15 years of working with over 100 biotechnology and diagnostic companies, SBH Sciences has earned a reputation for product quality, service and on-time delivery. SBH Sciences has partnered with early-stage biotechnology companies, We provide these companies with: incubator-model support, cell-based discovery, cytokine and enzyme production, as well as immunological and analytical services.

SBH Sciences provides cell-based discovery and preclinical process development services based on its expertise in cell culture, biologic production, and biomarker development. The company’s extensive, innovative cell based cytokine, kinase and cancer drug profiling assays (using over 180 human cancer cell lines), provide time and cost effective tools for screening drug candidates and optimizing therapeutics leads mainly in Oncology and Inflammation. SBH Sciences has comprehensive preclinical production capabilities for biologics, from DNA to final pure active product. Moreover, the company’s immunological expertise provides a rapid path to biomarker discovery, optimization and implementation of new diagnostics tools.

Our array of cytokine bioassay service is the most comprehensive in the US and includes over 280 bioassays that can accelerate discovery and biopharma development programs. Moreover, our proprietary processes have achieved commercial production of 31 highly purified recombinant cytokines, 6 Glycosyltransferase Enzymes and 33 monoclonal antibodies, currently sold to the scientific community worldwide.  SBH Sciences is a member of the Massachusetts Biotechnology Council and is based in Natick, MA. SBH Sciences Registered with CLIA in 2011.